COST Action CA18218

[Webinar] Estimating the non-fatal burden of cancer: methodologies of national BoD studies

Wednesday 12 June 2024, 11h-12h CET

About the webinar

Driven by the impact of the Global Burden of Disease study, several countries have decided to establish a national burden of disease study. Central to any national burden of disease study is the establishment of a coherent framework for routinely quantifying the impact of diseases and risk factors in terms of DALYs. Within this webinar, you will hear about two inspirational examples of national burden of disease studies and their use of national data to estimate the non-fatal burden of different types of cancers. You will learn about the methodological frameworks chosen by each study with their strengths and weaknesses.

Programme

11h00 Welcome and Introduction
— Vanessa Gorasso, Sciensano, Belgium
11h10 Estimating severity distributions for cancer disease models for the German BoD study
— Elena von der Lippe, Robert Koch Institute, Germany
Download the presentation
11h30 Transforming incidence intro prevalence using microsimulation: the non-fatal burden of cancer in the Belgian BoD study
— Robby De Pauw, Sciensano, Belgium
Download the presentation
11h50 General discussion

Speakers

Elena von der Lippe

Dr. Elena von der Lippe is a scientific researcher at the Robert Koch Institute (RKI) in Berlin, Germany. She studied statistics and obtained her PhD in Demography. She has been working in RKI since 2008 in the Department of Epidemiology and Health Monitoring. She has worked on the conception, organization, quality assessment and analysis of different epidemiological studies conducted at RKI. Since 2015 she is involved in Burden of Disease assessments and is the methodological leader of the Germany BURDEN2020 Project.

Robby De Pauw

Dr. Robby De Pauw is a senior scientist at Sciensano and post-doctoral researcher in Rehabilitation Sciences at Ghent University. He conducts policy-driven public health research in the domain of composite measures of population health and rehabilitation. Currently, he is working on the Belgian National Burden of Disease Study. Robby holds PhD degrees in Health Sciences, and MSc degrees in Biostatistics and Physiotherapy and Rehabilitation Sciences.

About COST

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. COST Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. Read more via cost.eu.

Get in touch

COST logo

Funded by the European Union

Website by  woluweb mini